Chemoprevention using dutasteride: the REDUCE trial
LG Gomella - Current Opinion in Urology, 2005 - journals.lww.com
Current Opinion in Urology, 2005•journals.lww.com
Proof of principle has been demonstrated by the Prostate Cancer Prevention Trial that a
chemoprevention strategy using a hormonal agent such as a 5α-reductase inhibitor can be
effective. The REDUCE trial will use the dual 5α-reductase inhibitor dutasteride in a group of
men identified at increased risk of developing prostate cancer to determine if this will be an
effective chemoprevention strategy.
chemoprevention strategy using a hormonal agent such as a 5α-reductase inhibitor can be
effective. The REDUCE trial will use the dual 5α-reductase inhibitor dutasteride in a group of
men identified at increased risk of developing prostate cancer to determine if this will be an
effective chemoprevention strategy.
Summary
Proof of principle has been demonstrated by the Prostate Cancer Prevention Trial that a chemoprevention strategy using a hormonal agent such as a 5α-reductase inhibitor can be effective. The REDUCE trial will use the dual 5α-reductase inhibitor dutasteride in a group of men identified at increased risk of developing prostate cancer to determine if this will be an effective chemoprevention strategy.
Lippincott Williams & Wilkins